ATRI - AtriCure: Steady Growth Lackluster Margins
AtriCure (ATRI) is a company not well-covered on this platform. Early 2017, I last reviewed the investment outlook for the shares as I concluded that management would need to find a cure for continued losses. Steady revenue growth and expectations of investors that the business would become profitable have been driving shares higher between 2017 and now, allowing management to continuously issue some shares at reasonable levels to raise necessary cash.
Here and now, the bottom-line results are still not impressive, although steady and continued revenue growth is compelling to shareholders, with valuations being perhaps